Get access

PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage

Authors

  • Giorgio Cattoretti,

    Corresponding author
    1. Institute for Cancer Genetics, Columbia University, New York, USA
    2. Department of Pathology, Columbia University Medical Center, New York, USA
    • Institute for Cancer Genetics, 1150 St Nicholas Avenue, Russ Berrie Science Pavilion, rm 301, Columbia University, New York, NY 10032, USA.
    Search for more papers by this author
  • Cristina Angelin-Duclos,

    1. Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York, USA
    Search for more papers by this author
  • Rita Shaknovich,

    1. Department of Pathology, Columbia University Medical Center, New York, USA
    Current affiliation:
    1. Department of Pathology, Albert Einstein College of Medicine, New York, USA.
    Search for more papers by this author
  • Huiping Zhou,

    1. Functional Genomics Division, Columbia Genome Center, Columbia University, New York, USA
    Search for more papers by this author
  • Denong Wang,

    1. Departments of Genetics, and Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
    Search for more papers by this author
  • Bachir Alobeid

    1. Department of Pathology, Columbia University Medical Center, New York, USA
    Search for more papers by this author

Abstract

PRDM1/Blimp-1 (in human and mouse, respectively) has a central role in determining and shaping the secretory arm of mature B-cell differentiation. In this study, a mouse monoclonal antibody that recognizes PRDM1 was used to detail its distribution in normal human lymphoid tissue and in lymphoid neoplasms that correspond to different stages of B-cell differentiation. PRDM1 was expressed in germinal centre blasts that co-express Pax5, CD19, CD20, and CD10, but not BCL6 or MTA-3. Pax5 was downregulated and full plasma cell morphology and phenotype were acquired by PRDM1+, nuclear cREL, pre-plasma cells upon exit from the germinal centre. Activated extrafollicular B-cells (CD30+, Pax5+) were largely PRDM1. PRDM1 was also absent in tissue histiocytes and the majority of resting T-cells and S-100+ antigen-presenting cells. PRDM1 and CD138 were expressed simultaneously in human lymphomas with plasma cell differentiation, but not in marginal zone lymphomas or chronic lymphocytic leukaemias. A minority of diffuse large B-cell lymphomas expressed PRDM1 and Hodgkin lymphomas were largely PRDM1. Infiltrating T-cells in PRDM1 B-cell lymphomas expressed PRDM1. In conclusion, PRDM1 staining is a reliable and informative assay to define plasma cell commitment and differentiation in human normal and neoplastic B-cell lineages. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Ancillary